274
Views
5
CrossRef citations to date
0
Altmetric
Review

Barriers and Strategies: A Review of Access to Affordable Multi-Drug Resistant Tuberculosis Medication in China

, , , , ORCID Icon, & ORCID Icon show all
Pages 3679-3687 | Published online: 19 Oct 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Liang Du, Yu Zhang, Xintong Lv, Yuxin Duan, Xiaoyan Shi, Haoqiang Ji, Ruiheng Wu, Jia Xu, Xu Chen, Yang Gao, Xiwei Lu & Ling Zhou. (2021) Prevalence of Multidrug-Resistant Tuberculosis in Dalian, China: A Retrospective Study. Infection and Drug Resistance 14, pages 1037-1047.
Read now

Articles from other publishers (4)

Pham Hien Trang Tu, Degefaye Zelalem Anlay, Anzaan Dippenaar, Emilyn Costa Conceição, Jasna Loos & Annelies Van Rie. (2022) Bedaquiline resistance probability to guide treatment decision making for rifampicin-resistant tuberculosis: insights from a qualitative study. BMC Infectious Diseases 22:1.
Crossref
Peize ZhangJie TanYi LinHailin ZhangGuofang DengXiaoyou Chen. (2022) Linezolid for patients with multidrug-resistant tuberculosis/extensively drug-resistant tuberculosis in China. Drug Discoveries & Therapeutics 16:2, pages 96-98.
Crossref
Mohsen Heidary, Maryam Shirani, Melika Moradi, Mehdi Goudarzi, Ramin Pouriran, Tayebe Rezaeian & Saeed Khoshnood. (2022) Tuberculosis challenges: Resistance, co-infection, diagnosis, and treatment. European Journal of Microbiology and Immunology 12:1, pages 1-17.
Crossref
Wei-Xi Jiang, Zhi-Peng Li, Qi Zhao, Meng-Qiu Gao, Qian Long, Wei-Bing Wang, Fei Huang, Ni Wang & Sheng-Lan Tang. (2021) Impacts of a comprehensive tuberculosis control model on the quality of clinical services and the financial burden of treatment for patients with drug-resistant tuberculosis in China: a mixed-methods evaluation. Infectious Diseases of Poverty 10:1.
Crossref